ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: View All • a b c d e [f] g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1625

Factor VIII as a Potential Biomarker of Disease Activity in Relapsing Polychondritis
Abstract Number: 2226

Factors Associated with Contraceptive Counseling by Rheumatologists for Reproductive-Aged Female Patients Prescribed Teratogenic Medications
Abstract Number: 0714

Factors Associated With Depression And Anxiety In ANCA-Associated Vasculitis Patients: Data From The Almenara Vasculitis Cohort
Abstract Number: 2378

Factors Associated With Fatigue In Systemic Lupus Erythematosus: Data From The Almenara Lupus Cohort
Abstract Number: 1014

Factors Associated with Fibromyalgia Diagnosis amongst People Meeting Criteria: Results from UK Biobank
Abstract Number: 1036

Factors Associated With Long-term Remission After Drug Discontinuation In IgG4-related Disease: A 3-Year Rule
Abstract Number: 2563

Factors Associated With Medication Use in the Preconception and Perinatal Period Among Women With Autoimmune Disorders: A Systematic Review
Abstract Number: 1018

Factors Associated with Mortality in Systemic Lupus Erythematosus under a Universal Healthcare System: Results from the CAPTURED Study, a Population-Based Cohort in Catalonia, Spain
Abstract Number: 0368

Factors Associated with Patient Acceptability of Rheumatology Care Delivered by Telemedicine
Abstract Number: 1566

Factors Associated with Patient and Physician Global Assessments in Early Systemic Sclerosis
Abstract Number: 2138

Factors driving therapeutic decision-making in Still’s Disease: When to Start and When to Stop? Data from the METAPHOR Project Worldwide Survey
Abstract Number: 0576

Factors impacting progression from oligoarticular to polyarticular PsA: Data from the FOREMOST study
Abstract Number: 2380

Factors Influencing Time to Diagnosis in Systemic Lupus Erythematosus: A Real-World Retrospective Analysis
Abstract Number: 2224

Failure of Steroid and Antimalarial Therapy to Normalize Placental Interferon and Angiogenic Gene Expression in SLE
Abstract Number: 0761

Fast-Track Clinics Improve Visual Outcomes in Giant Cell Arteritis: A Meta-Analysis
Abstract Number: 1106

Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan
Abstract Number: 1875

Fcγ-receptor activation by circulating immune complexes in autoimmunity and CD19.CAR-T cell therapy
Abstract Number: 1491

Feasibility of Extrarenal Systemic Lupus Erythematosus Disease Modification in GLADEL 2.0, a Latin American Cohort
Abstract Number: 2075

Ferritin trends differentiate anti-MDA5 Dermatomyositis from anti-Jo1 Antisynthetase Syndrome
Abstract Number: 2655

Fetal and maternal outcomes in systemic sclerosis and very early diagnosis of systemic sclerosis pregnancies, a national prospective study
Abstract Number: 0750

Fibrinogen as a biomarker in the diagnosis of giant cell arteritis and detection of flares
Abstract Number: 0921

Fibrinogen Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Promotes Pro-Inflammatory Macrophage Differentiation Through p38 and NF-κB Signaling
Abstract Number: 0346

Fibroblast Growth Factor-23 and Bone Status in Patients with Chronic Kidney Disease Compared to a Healthy Control Group and Its Relationship with Cardiovascular Risk
Abstract Number: 1919

Financial insecurity and discrimination are associated with patient-reported quality of life in patients with SLE
Abstract Number: 1850

First American SLE patients demonstrate enhanced lipid metabolism and B cell activation by high-content proteomic analyses
Abstract Number: 1677

First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care
Abstract Number: 2653

First Prospective Evaluation of Recombinant Herpes Zoster Vaccine in Systemic Sclerosis: Immunogenicity, Safety, and Disease Activity Outcomes
Abstract Number: 1462

Five-Year Results of Secukinumab on Minimal Disease Activity (MDA) Components and the Impact of Biologic Treatment Status on Effectiveness and Safety in Patients With Psoriatic Arthritis: Real-World Data From the SERENA Study
Abstract Number: 0821

Flipping The Switch – Classical Complement Activation closely linked to IFN-signalling in Stills Disease
Abstract Number: 2080

Foot laterality does not modify outcome of knee and/or hip osteoarthritis
Abstract Number: 0447

Foot-pressure distribution method for detection of foot joint arthritis in patients with rheumatic diseases
Abstract Number: 0059

Formyl Peptide Receptor 1 (FPR1) Influences Arthritis Severity in a Sex- and Compartment-Specific Manner
Abstract Number: 1275

Fostering connections in Pediatric Rheumatology: A Narrative medicine intervention
Abstract Number: LB10

Four-Year Safety and Efficacy of Deucravacitinib in Systemic Lupus Erythematosus: Results From a Phase 2 Program
Abstract Number: 0969

FOXO1 Mediated Polysialic Acid Dysregulation in Severe Systemic Sclerosis (SSc): A Novel Biomarker and Therapeutic Target?
Abstract Number: 0992

FoxP3Lo CD4+ T cells are functionally suppressive and expanded in the immune-mediated fibrotic diseases IgG4-related disease and systemic sclerosis
Abstract Number: 2119

Fracture rates in 6475 individuals with osteogenesis imperfecta stratified by age, sex and clinical severity
Abstract Number: 0246

Fracture Risk in Intestinal Autoimmune-mediated Diseases Patients: Clinical Insights from REMS
Abstract Number: 0338

Fractures and Changes in Bone Mineral Density During Two Years of Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis: A Systematic Literature Review and Individual Participant Data Meta-Analysis
Abstract Number: 0432

Frequency and Characteristics of Ophthalmologic Involvement in Patients with Rheumatoid Arthritis
Abstract Number: 0764

Frequency of large vessel vasculitis in giant cell arteritis with and without adventiitis of temporal artery – Is the presence of temporal arteritis sufficient to diagnose giant cell arteritis?-
Abstract Number: 2534

Frequency of Ocular and Gastrointestinal Lesions Is Increased in Japanese Behçet’s Disease Patients with HLA-B61
Abstract Number: 1813

Frequency of Tissue-Specific Activated CD8+ T Cells is Correlated To Disease Severity in Juvenile Idiopathic Arthritis
Abstract Number: PP12

From Invisibility to Advocacy: A Gout Patient’s Journey to Validation and Systemic Change
Abstract Number: 0305

From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy
Abstract Number: 2313

From Plaque to Plaque: Bridging Oral and Systemic Inflammation in Psoriasis and PsA
Abstract Number: 2581

From Skin to Kidney: Neutrophil-Mediated Crosstalk Links Cutaneous Injury to Renal Inflammation and Vascular Remodeling in Lupus
Abstract Number: 0509

Functional Anti-M3R Autoantibodies in Sjögren’s Disease: From Gland to Circulation
Abstract Number: 0920

Functional Characterization of NEMO-NDAS Causing Variants in Patients’ PBMCs and in Wildtype and Mutant U937 Cells
Abstract Number: 1725

Functional NOTCH4 Variants Drive Vasculopathy and Fibrosis in Systemic Sclerosis.
Abstract Number: 0585

Fungal Infections, Including Candida, in Patients With Active Axial Spondyloarthritis Treated With Secukinumab: A Pooled Analysis of 10 Phase 3 Trials
Abstract Number: 1459

Fungal Infections, Including Candida, in Patients With Active Psoriatic Arthritis (PsA) Treated With Secukinumab: A Pooled Analysis of 9 Phase 3 Trials

Jump to: View All • a b c d e [f] g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].